West Nile virus infections projected from blood donor screening data, United States, 2003

被引:118
作者
Busch, MP
Wright, DJ
Custer, B
Tobler, LH
Stramer, SL
Kleinman, SH
Prince, HE
Bianco, C
Foster, G
Petersen, LR
Nemo, G
Glynn, SA
机构
[1] Blood Syst Res Inst, San Francisco, CA 94118 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] WESTAT Corp, Rockville, MD 20850 USA
[4] Amer Red Cross, Natl Testing & Reference Labs, Gaithersburg, MD USA
[5] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[6] Focus Diagnost, Cypress, CA USA
[7] Amer Blood Ctr, Washington, DC USA
[8] Ctr Dis Control & Prevent, Ft Collins, CO USA
[9] NHLBI, Bethesda, MD 20892 USA
关键词
D O I
10.3201/eid1203.051287
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
National blood donor screening for West Nile virus (WNV) RNA using minipool nucleic acid amplification testing (MP-NAT) was implemented in the United States in July 2003. We compiled national NAT yield data and performed WNV immunoglobulin M (IgM) testing in 1 WNV-epidemic region (North Dakota). State-specific MP-NAT yield, antibody seroprevalence, and the average time RNA is detectable by MP-NAT were used to estimate incident infections in 2003. WNV donor screening yielded 944 confirmed viremic donors. MP-NAT yield peaked in August with > 0.5% of donations positive for WNV RNA in 4 states. Peak IgM seroprevalence for North Dakota was 5.2% in late September. The average time viremia is detectable by MP-NAT was 6.9 days (95% confidence interval [CI] 3.0-10.7). An estimated 735,000 (95% Cl 322,000-1,147,000) infections occurred in 2003, with 256 (95% Cl 112-401) infections per neuroinvasive case. In addition to preventing transfusion-transmitted WNV infection, donor screening can serve as a tool to monitor seasonal incidence in the general population.
引用
收藏
页码:395 / 402
页数:8
相关论文
共 31 条
[1]  
[Anonymous], 2006, SAS PROPR SOFTW REL
[2]   Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City [J].
Biggerstaff, BJ ;
Petersen, LR .
TRANSFUSION, 2002, 42 (08) :1019-1026
[3]   Screening the blood supply for west nile virus RNA by nucleic acid amplification testing [J].
Busch, MP ;
Caglioti, S ;
Robertson, EF ;
McAuley, JD ;
Tobler, LH ;
Kamel, H ;
Linnen, JM ;
Shyamala, V ;
Tomasulo, P ;
Kleinman, SH .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (05) :460-467
[4]   Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003 [J].
Busch, MP ;
Tobler, LH ;
Saldanha, J ;
Caglioti, S ;
Shyamala, V ;
Linnen, JM ;
Gallarda, J ;
Phelps, B ;
Smith, RIF ;
Drebot, M ;
Kleinman, SH .
TRANSFUSION, 2005, 45 (04) :492-499
[5]  
*CDCP, 2004, MMWR-MORBID MORTAL W, V53, P281
[6]  
*CDCP, 2004, STAT SURV CONTR 2003
[7]  
Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P916
[8]  
Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1129
[9]   Triggers for switching from minipool testing by nucleic acid technology to individual-donation nucleic acid testing for West Nile virus: Analysis of 2003 data to inform 2004 decision making [J].
Custer, B ;
Tomasulo, PA ;
Murphy, EL ;
Caglioti, S ;
Harpool, D ;
McEvoy, P ;
Busch, MP .
TRANSFUSION, 2004, 44 (11) :1547-1554
[10]   Emerging infections, transfusion safety, and epidemiologic [J].
Dodd, RY .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1205-1206